The expanding landscape of inflammatory cells affecting cancer therapy.
Journal
Nature biomedical engineering
ISSN: 2157-846X
Titre abrégé: Nat Biomed Eng
Pays: England
ID NLM: 101696896
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
29
08
2019
accepted:
04
02
2020
pubmed:
24
3
2020
medline:
22
7
2020
entrez:
24
3
2020
Statut:
ppublish
Résumé
Tumour-infiltrating myeloid cells (TIMCs) are critical regulators of cancer growth. The different phenotypes, functions and therapeutic effects of these phagocytes have, however, been difficult to study. With the advent of single-cell-based technologies, a new 'worldview' is emerging: the classification of TIMCs into subtypes that are conserved across patients and across species. As the landscape of TIMCs is beginning to be understood, it opens up questions about the function of each TIMC subtype and its drugability. In this Perspective, we outline the current map of TIMC populations in cancer and their known and presumed functions, and discuss their therapeutic implications and the biological research questions that they give rise to. The answers should be particularly relevant for bioengineers, materials scientists and the chemical and pharmaceutical communities developing the next generation of cancer therapies.
Identifiants
pubmed: 32203281
doi: 10.1038/s41551-020-0524-y
pii: 10.1038/s41551-020-0524-y
pmc: PMC7405944
mid: NIHMS1612572
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
489-498Subventions
Organisme : NCI NIH HHS
ID : P01 CA069246
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206997
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218579
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA236561
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204019
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA240239
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA224348
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI084880
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA202637
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206890
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
pubmed: 27339708
Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317–1334 (2019).
pubmed: 6620049
pmcid: 6620049
Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).
pubmed: 29988129
Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765 (2017).
pubmed: 28475900
pmcid: 5737939
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).
pubmed: 30388456
pmcid: 30388456
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
pubmed: 27124452
pmcid: 27124452
Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624 (2017).
pubmed: 29198524
pmcid: 29198524
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 (2017).
pubmed: 28475899
pmcid: 5422211
Chung, W. et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 8, 15081 (2017).
pubmed: 28474673
pmcid: 5424158
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 (2018).
pubmed: 29961579
pmcid: 6348010
Müller, S. et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 18, 234 (2017).
pubmed: 29262845
pmcid: 5738907
Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355, eaai8478 (2017).
pubmed: 28360267
pmcid: 5519096
Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J. & Biswas, S. K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17, 34–40 (2016).
pubmed: 26681460
Gordon, S. & Plüddemann, A. The mononuclear phagocytic system. Generation of diversity. Front. Immunol. 10, 1893 (2019).
pubmed: 31447860
pmcid: 6696592
Baron, M. et al. A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure. Cell Syst. 3, 346–360 (2016).
pubmed: 5228327
pmcid: 5228327
Tsoucas, D. et al. Accurate estimation of cell-type composition from gene expression data. Nat. Commun. 10, 2975 (2019).
pubmed: 31278265
pmcid: 6611906
Wang, X., Park, J., Susztak, K., Zhang, N. R. & Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat. Commun. 10, 380 (2019).
pubmed: 30670690
pmcid: 6342984
Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588–602 (2019).
pubmed: 30930117
pmcid: 6472943
Etzerodt, A. et al. Specific targeting of CD163
pubmed: 31375534
pmcid: 6781002
Villani, A. C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).
pubmed: 28428369
pmcid: 5775029
Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161 (2018).
pubmed: 30552023
pmcid: 6301092
Eisenbarth, S. C. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19, 89–103 (2019).
pubmed: 30464294
pmcid: 7755085
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).
pubmed: 25446897
pmcid: 4254577
Ruffell, B. et al. Macrophage IL-10 blocks CD8
pubmed: 25446896
pmcid: 25446896
Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178–1191 (2018).
pubmed: 29942093
pmcid: 6475503
Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4
pubmed: 30955881
pmcid: 6954108
Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001).
pubmed: 11257139
pmcid: 2193412
Wu, Y., Li, Y. Y., Matsushima, K., Baba, T. & Mukaida, N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol. 181, 6384–6393 (2008).
pubmed: 18941229
Engblom, C. et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF
pubmed: 29191879
pmcid: 29191879
Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
pubmed: 28855077
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
pubmed: 22437938
pmcid: 3587148
Fleming, V. et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. 9, 398 (2018).
pubmed: 29552012
pmcid: 5840207
Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16, 431–446 (2016).
pubmed: 27282249
Ovais, M., Guo, M. & Chen, C. Tailoring nanomaterials for targeting tumor-associated macrophages. Adv. Mater. 31, e1808303 (2019).
pubmed: 30883982
Miller, M. A. & Weissleder, R. Imaging of anticancer drug action in single cells. Nat. Rev. Cancer 17, 399–414 (2017).
pubmed: 28642603
pmcid: 7552440
Miller, M. A. & Weissleder, R. Imaging the pharmacology of nanomaterials by intravital microscopy: toward understanding their biological behavior. Adv. Drug Deliv. Rev. 113, 61–86 (2017).
pubmed: 27266447
Ng, T. S. C., Garlin, M. A., Weissleder, R. & Miller, M. A. Improving nanotherapy delivery and action through image-guided systems pharmacology. Theranostics 10, 968–997 (2020).
pubmed: 31938046
pmcid: 6956809
Rodell, C. B., Koch, P. D. & Weissleder, R. Screening for new macrophage therapeutics. Theranostics 9, 7714–7729 (2019).
pubmed: 31695796
pmcid: 6831478
Haney, M. S. et al. Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat. Genet 50, 1716–1727 (2018).
pubmed: 30397336
pmcid: 6719718
Wang, S. J. et al. Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. Sci. Adv. (in the press).
Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad. Sci. USA 109, 6662–6667 (2012).
pubmed: 22451913
pmcid: 3340046
Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76–84 (2018).
pubmed: 29180808
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).
pubmed: 31367043
pmcid: 31367043
Advani, R. et al. CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
pubmed: 30380386
pmcid: 8058634
Logtenberg, M. E. W. et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat. Med. 25, 612–619 (2019).
pubmed: 30833751
pmcid: 7025889
Miller, M. A. et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci. Transl. Med. 9, eaal0225 (2017).
pubmed: 28566423
pmcid: 6681815
Miller, M. A. et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 6, 8692 (2015).
pubmed: 26503691
pmcid: 4711745
Arwert, E. N. et al. A unidirectional transition from migratory to perivascular macrophage is required for tumor cell intravasation. Cell Rep. 23, 1239–1248 (2018).
pubmed: 29719241
pmcid: 5946803
Linde, N. et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat. Commun. 9, 21 (2018).
pubmed: 29295986
pmcid: 5750231
Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017).
pubmed: 28490665
pmcid: 5734617
DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369–382 (2019).
pubmed: 30718830
pmcid: 7339861
Cassier, P. A. et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 16, 949–956 (2015).
pubmed: 26179200
Spiegel, A. et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 6, 630–649 (2016).
pubmed: 27072748
pmcid: 4918202
Cortez-Retamozo, V. et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 38, 296–308 (2013).
pubmed: 23333075
pmcid: 3582771
Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1020–1027 (2019).
pubmed: 31145418
pmcid: 6547247
Rodell, C. B. et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578–588 (2018).
pubmed: 31015631
pmcid: 6192054
Downey, C. M., Aghaei, M., Schwendener, R. A. & Jirik, F. R. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2’3’-cGAMP, induces M2 macrophage repolarization. PLoS ONE 9, e99988 (2014).
pubmed: 24940883
pmcid: 4062468
Kather, J. N. & Halama, N. Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br. J. Cancer 120, 871–882 (2019).
pubmed: 30936499
pmcid: 6734657
Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637–650 (2011).
pubmed: 21616434
pmcid: 21616434
King, K. R. et al. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat. Med. 23, 1481–1487 (2017).
pubmed: 6477926
pmcid: 6477926
DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
pubmed: 22039576
pmcid: 3203524
Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264–1272 (2013).
pubmed: 24056773
pmcid: 3840724
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
Salmon, H. et al. Expansion and activation of CD103
pubmed: 27096321
pmcid: 4980762
Momin, N. et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci. Transl. Med. 11, eaaw2614 (2019).
pubmed: 31243150
pmcid: 7811803
Jahan, N., Talat, H. & Curry, W. T. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. Neuro Oncol. 20, 44–54 (2018).
pubmed: 29016879
Ma, H. S. et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol. Res. 7, 428–442 (2019).
pubmed: 30642833
pmcid: 6397686
Sun, S. C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545–558 (2017).
pubmed: 28580957
pmcid: 5753586
Vonderheide, R. H. The immune revolution: a case for priming, not checkpoint. Cancer Cell 33, 563–569 (2018).
pubmed: 29634944
pmcid: 5898647
Dougan, S. K. & Dougan, M. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy 10, 787–796 (2018).
pubmed: 29807457
pmcid: 6462841
Koch, P. D., Rodell, C. B., Kohler, R. H., Pittet, M. & Weissleder, R. Myeloid cell-targeted nanocarriers efficiently inhibit cellular inhibitor of apoptosis for cancer immunotherapy. Cell Chem. Biol. 16, 95–104 (2020).
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
pubmed: 26343581
pmcid: 26343581
Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).
pubmed: 26073941
pmcid: 4580135
Nathan, C. F., Silverstein, S. C., Brukner, L. H. & Cohn, Z. A. Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J. Exp. Med. 149, 100–113 (1979).
pubmed: 216763
Urban, J. L., Shepard, H. M., Rothstein, J. L., Sugarman, B. J. & Schreiber, H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl Acad. Sci. USA 83, 5233–5237 (1986).
pubmed: 3487788
pmcid: 323925
Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16, 183–194 (2009).
pubmed: 19732719
pmcid: 19732719
Matlung, H. L. et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 23, 3946–3959e6 (2018).
pubmed: 29949776
Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120–135 (2016).
pubmed: 27374224
pmcid: 4945447
Ponzetta, A. et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell 178, 346–360 (2019).
pubmed: 31257026
pmcid: 6630709
Magnuson, A. M. et al. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc Natl Acad. Sci. USA 115, E10672–E10681 (2018).
pubmed: 30348759
pmcid: 6233093
Ståhl, P. L. et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 353, 78–82 (2016).
Vickovic, S. et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat. Methods 16, 987–990 (2019).
pubmed: 6765407
pmcid: 6765407
Finotello, F., Rieder, D., Hackl, H. & Trajanoski, Z. Next-generation computational tools for interrogating cancer immunity. Nat. Rev. Genet. 20, 724–746 (2019).
pubmed: 31515541
Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491–2496 (2012).
pubmed: 22308361
pmcid: 3289379
Pittet, M. J., Garris, C. S., Arlauckas, S. P. & Weissleder, R. Recording the wild lives of immune cells. Sci. Immunol. 3, eaaq0491 (2018).
pubmed: 30194240
pmcid: 6771424
Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728–5739 (2010).
pubmed: 20570887
Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).
pubmed: 22442384
Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 323–338 (2017).
pubmed: 28813661
pmcid: 5578409
Loyher, P. L. et al. Macrophages of distinct origins contribute to tumor development in the lung. J. Exp. Med. 215, 2536–2553 (2018).
pubmed: 30201786
pmcid: 6170177
Laviron, M. & Boissonnas, A. Ontogeny of tumor-associated macrophages. Front. Immunol. 10, 1799 (2019).
pubmed: 31417566
pmcid: 6684758
Sharma, M. D. et al. Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c
pubmed: 29343444
pmcid: 6005382
Marigo, I. et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30, 377–390 (2016).
pubmed: 27622331
pmcid: 5023283
La Manno, G. et al. RNA velocity of single cells. Nature 560, 494–498 (2018).
pubmed: 6130801
pmcid: 6130801
Giedt, R. J. et al. Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens. Nat. Commun. 9, 4550 (2018).
pubmed: 30382095
pmcid: 6208406
Kim, H. Y. et al. Quantitative imaging of tumor-associated macrophages and their response to therapy using
pubmed: 30508377
pmcid: 6482841
Stuart, T. & Satija, R. Integrative single-cell analysis. Nat. Rev. Genet. 20, 257–272 (2019).
pubmed: 30696980
Stubbington, M. J. T., Rozenblatt-Rosen, O., Regev, A. & Teichmann, S. A. Single-cell transcriptomics to explore the immune system in health and disease. Science 358, 58–63 (2017).
pubmed: 28983043
pmcid: 5654495
Heath, J. R., Ribas, A. & Mischel, P. S. Single-cell analysis tools for drug discovery and development. Nat. Rev. Drug Discov. 15, 204–216 (2016).
pubmed: 26669673
Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 (2012).
pubmed: 22378047
pmcid: 3287223
Perdiguero, E. G. & Geissmann, F. The development and maintenance of resident macrophages. Nat. Immunol. 17, 2–8 (2016).
pubmed: 26681456
pmcid: 4950995
Mantovani, A. & Allavena, P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212, 435–445 (2015).
pubmed: 25753580
pmcid: 4387285
Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 392–404 (2014).
pubmed: 24854589
Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. Science 350, 985–990 (2015).
pubmed: 26494174
pmcid: 4869713
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
pubmed: 26193342
pmcid: 4852857
Albrengues, J. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361, eaao4227 (2018).
pubmed: 30262472
pmcid: 6777850
Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553–557 (2019).
pubmed: 30728496
Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572, 538–542 (2019).
pubmed: 31367040
pmcid: 6707815
Granot, Z. et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300–314 (2011).
pubmed: 21907922
pmcid: 3172582
Weinreb, C., Wolock, S. & Klein, A. M. SPRING: a kinetic interface for visualizing high dimensional single-cell expression data. Bioinformatics 34, 1246–1248 (2018).
pubmed: 29228172